Skip to main content
H. Lundbeck A logo

H. Lundbeck A — Investor Relations & Filings

Ticker · HLUN ISIN · DK0061804770 LEI · 5493006R4KC2OI5D3470 CO Manufacturing
Open in API
Filings indexed 947 across all filing types
Latest filing 2023-02-08 Annual Report
Country DK Denmark
Listing CO HLUN

About H. Lundbeck A

https://www.lundbeck.com/global

H. Lundbeck A/S is a global biopharmaceutical company specializing in brain diseases. The company is engaged in the research, development, manufacturing, and marketing of transformative therapies for a range of psychiatric and neurological disorders. Its portfolio and pipeline focus on conditions such as depression, mood disorders, and rare childhood-onset epilepsies. Lundbeck is dedicated to advancing neuroscience to improve the quality of life for individuals affected by central nervous system disorders.

Recent filings

Filing Released Lang Actions
Lundbeck Annual Report 2022
Annual Report Classification · 100% confidence The document is clearly identified as the 'Annual Report 2022' for H. Lundbeck A/S. It contains comprehensive sections including a Management Review, Financial Key Figures, Sustainability Key Figures, a Letter to Shareholders, and Consolidated Financial Statements. This aligns perfectly with the definition of an Annual Report (10-K). FY 2022
2023-02-08 English
Earnings Release 2022
Earnings Release Classification · 100% confidence The document is a press release dated February 7, 2023, announcing Lundbeck's financial guidance for 2023 and mid-term financial targets, following strong 2022 performance. It provides specific revenue and EBITDA guidance figures for 2023 and discusses preliminary 2022 results. This content—announcing forward-looking financial expectations and summarizing recent performance highlights—is characteristic of an Earnings Release (ER). Although it mentions the full Annual Report 2022 will be published the next day (February 8, 2023), this document itself is the preliminary announcement of results and guidance, not the comprehensive 10-K or the announcement of the 10-K's release (RPA). FY 2022
2023-02-07 English
Lundbeck announces financial guidance for 2023 and mid-term financial targets that build on very strong 2022 performance
Earnings Release Classification · 100% confidence The document is a 'Corporate Release' from H. Lundbeck A/S that provides preliminary 2022 financial performance figures and sets financial guidance for 2023. It explicitly states that the full annual report will be published the following day. Because this document serves as the initial announcement of financial results and guidance rather than the full audited report, it is classified as an Earnings Release (ER). FY 2022
2023-02-07 English
Regulatory Filings 2023
Regulatory Filings Classification · 100% confidence The document is a press release titled "Lundbeck announces FDA acceptance and priority review of sNDA for brexpiprazole...". It details a regulatory milestone (FDA acceptance of a supplemental New Drug Application - sNDA) and provides key clinical and commercial updates related to a drug. This type of announcement, which communicates significant operational or regulatory news outside of routine financial reporting (like 10-K or IR), is typically classified as a general Regulatory Filing (RNS) or, if it were focused purely on financial results, an Earnings Release (ER). Since it is a specific announcement about regulatory progress and not a full financial report, earnings summary, or management discussion, RNS is the most appropriate general regulatory category for this type of corporate news release distributed via a service like Cision. The document length is substantial (8778 chars), so it is not a simple RPA.
2023-01-07 English
Lundbeck announces FDA acceptance and priority review of sNDA for brexpiprazole for the treatment of agitation associated with Alzheimer’s dementia
Regulatory Filings Classification · 95% confidence The document is a corporate release from H. Lundbeck A/S announcing that the FDA has accepted and granted priority review for a supplemental New Drug Application (sNDA) for the drug brexpiprazole. This is a standard regulatory announcement regarding product development and FDA status, which falls under the category of general regulatory announcements for filings that do not fit into specific financial reporting or governance categories.
2023-01-07 English
Earnings Release 2022
Earnings Release Classification · 95% confidence The document is titled 'Corporate Release' and announces that H. Lundbeck A/S 'raises financial guidance range for the full year 2022'. It provides a table comparing actual FY 2021 results, previous 2022 guidance, and the revised 2022 guidance for key metrics like Revenue, EBITDA, and EBIT. This is a specific announcement regarding financial outlook updates, not the full periodic report (10-K or IR) or the initial summary release (ER). It is a forward-looking financial update. Since there is no specific code for 'Guidance Update', the closest fit among the provided options that deals with financial performance updates, but is not a full report or an earnings release summary, is difficult. However, the content is a direct announcement of financial expectations changing. It is not a Call Transcript (CT), Earnings Release (ER) which usually covers past performance, or an Interim Report (IR). Given the nature of raising future financial guidance, it functions as a significant financial update. If this were a US filer, it might be an 8-K item, but among the provided codes, 'ER' (Earnings Release) is often used broadly for periodic financial news, but this is specifically a *guidance raise* outside of the standard quarterly release cycle (which is noted to be published the next day). Since it is a corporate release announcing a change in financial expectations, it is most closely aligned with an Earnings Release (ER) in function, as it communicates key financial metrics and outlook changes, even if it's not the full earnings report itself. Alternatively, it could be classified as a general Regulatory Filing (RNS) if ER is strictly reserved for the official quarterly/annual results announcement. Given the high specificity of the financial data presented (revised guidance table), it is more substantial than a simple RNS. I will classify it as ER as it is a major financial performance communication, though it is a pre-release update to guidance. FY 2022
2022-11-08 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.